Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360687 | 1.00 | LPAR3 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5356910 | 1.00 | LPAR3 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5360694 | 1.00 | LPAR3 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5353206 | 0.92 | LPAR3 (0.61) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5353213 | 0.92 | LPAR3 (0.61) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5351183 | 0.89 | LPAR1 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL4312200 | 0.89 | LPAR1 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5360200 | 0.89 | LPAR1 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL5351186 | 0.89 | LPAR1 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 | |
| SCHEMBL4312196 | 0.89 | LPAR1 (0.60) | LPAR3LPAR1ENPP2FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | LPAR3 36/4885LPAR1 42/4885ENPP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.